Bevacizumab for the treatment of non-small-cell lung cancer (terminated appraisal)

NICE technology appraisals [TA148] Published date:

NICE is unable to recommend the use in the NHS of bevacizumab in addition to platinum-based chemotherapy for the first-line treatment of patients with unresectable advanced, metastatic or recurrent non-small-cell lung cancer (other than predominantly squamous cell histology) because no evidence submission was received from the manufacturer or sponsor of the technology.

Get involved